Shortening therapy duration with direct-acting antiviral agents (DAAs) is desirable to pursue the WHO target of HCV eradication by 2030. We report two cases of HCV-infected women who achieved sustained virologic response after an ultra-short treatment with glecaprevir/pibrentasvir (G/P), discontinued due to cutaneous adverse events, and analyze similar cases reported in the literature. Female gender seems to be a prevailing characteristic in this group of patients. G/P, due to its pangenotypic and strong antiviral activity, may represent a candidate for a shortened DAA regimen in non-cirrhotic treatment-naive subjects.
Glecaprevir/pibrentasvir ultra-short treatment to cure HCV infection: case report and literature review / Volpicelli, Lorenzo; Biliotti, Elisa; Milito, Cinzia; Cruciata, Alessia; Spaziante, Martina; Rivano Capparuccia, Marco; Taliani, Gloria; Mezzaroma, Ivano. - In: LE INFEZIONI IN MEDICINA. - ISSN 1124-9390. - 28:4(2020), pp. 616-620.
Glecaprevir/pibrentasvir ultra-short treatment to cure HCV infection: case report and literature review
Volpicelli, Lorenzo
;Biliotti, Elisa;Milito, Cinzia;Cruciata, Alessia;Spaziante, Martina;Rivano Capparuccia, Marco;Taliani, Gloria;Mezzaroma, Ivano
2020
Abstract
Shortening therapy duration with direct-acting antiviral agents (DAAs) is desirable to pursue the WHO target of HCV eradication by 2030. We report two cases of HCV-infected women who achieved sustained virologic response after an ultra-short treatment with glecaprevir/pibrentasvir (G/P), discontinued due to cutaneous adverse events, and analyze similar cases reported in the literature. Female gender seems to be a prevailing characteristic in this group of patients. G/P, due to its pangenotypic and strong antiviral activity, may represent a candidate for a shortened DAA regimen in non-cirrhotic treatment-naive subjects.File | Dimensione | Formato | |
---|---|---|---|
Volpicelli_Glecaprevir_2020.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
553.79 kB
Formato
Adobe PDF
|
553.79 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.